
CLAIMS

1. Use of a RXR agonist of Formula I,




(Formula I)

wherein R is H, or lower alkyl of 1 to 6 carbons; or a pharmaceutically-acceptable salt thereof in the preparation of a medicament, for treating a patient with $Her2^+$ cancer, and

wherein the patient has received, is receiving, or is scheduled to receive a Her2-targeted therapeutic agent, and wherein the Her2-targeted therapeutic agent is an anti-Her2 antibody or a Her2 kinase inhibitor selected from lapatinib or neratinib.

2. Use of a RXR agonist of Formula I,



(Formula I)


wherein R is H, or lower alkyl of 1 to 6 carbons; or a pharmaceutically-acceptable salt thereof, in the preparation of a medicament for treating a patient with $Her2^+$ cancer, and

wherein the RXR agonist is to be used in combination with a Her2-targeted therapeutic agent, and wherein the Her2-targeted therapeutic agent is an anti-Her2 antibody or a Her2 kinase inhibitor selected from lapatinib or neratinib.

3. The use of any one of claims 1 or 2, wherein a thyroid hormone is to be administered in conjunction with the RXR agonist.

4. The use of claim 3, wherein the thyroid hormone is thyroxine.

5. The use of any one of claims 1-4, wherein the RXR agonist is a compound of Formula II




(Formula II).

6. The use of any one of claims 1-5, wherein the anti-Her2 antibody is trastuzumab or pertuzumab.

7. The use of any one of claims 1-5, wherein the Her2-targeted therapeutic agent is an antibody-drug conjugate comprising the anti-Her2 antibody.

8. The use of claim 7, wherein the antibody-drug conjugate is ado-trastuzumab emtansine.

9. A combination comprising a Her2-targeted therapeutic agent and a RXR agonist of Formula I,




(Formula I)

wherein R is H, or lower alkyl of 1 to 6 carbons; or a pharmaceutically-acceptable salt thereof; and

wherein the Her2-targeted therapeutic agent is an anti-Her2 antibody or a Her2 kinase inhibitor selected from lapatinib or neratinib.

10. The combination of claim 9, further comprising thyroid hormone.

11. The combination of claim 9, wherein the RXR agonist is a compound of Formula II



(Formula II).

12. The combination of claim 9, wherein the anti-Her2 antibody is selected from trastuzumab or pertuzumab.

13. The combination of claim 9, wherein the Her2-targeted therapeutic agent is an antibody-drug conjugate comprising the anti-Her2 antibody.

14. The combination of claim 13, wherein the antibody-drug conjugate is ado-trastuzumab emtansine.